Can-Fite BioPharma logo

Can-Fite BioPharmaNYSE American: CANF

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Israel

IPO:

06 November 2012

Next earnings report:

29 November 2024

Last dividends:

N/A

Next dividends:

N/A
$11.95 M
-72%vs. 3y high
20%vs. sector
-vs. 3y high
-vs. sector
-52%vs. 3y high
81%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 20 Nov 2024 22:05:01 GMT
$1.96-$0.07(-3.45%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

CANF Latest News

Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson
globenewswire.com18 October 2024 Sentiment: POSITIVE

Data Reported by Can-Fite Veterinary Partner Vetbiolix who already exercised its option for a full license deal worth $325M

Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health
globenewswire.com16 September 2024 Sentiment: POSITIVE

Study will aim to establish safety and clinical efficacy PETACH TIKVA, Israel, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.

Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
globenewswire.com29 August 2024 Sentiment: POSITIVE

RAMAT GAN, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results and clinical updates for H1 2024.

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
accesswire.com09 August 2024 Sentiment: POSITIVE

ORLANDO, FL / ACCESSWIRE / August 9, 2024 / RedChip Companies will air interviews with OS Therapies Inc. (NYSE American:OSTX) and Can-Fite BioPharma Ltd. (NYSE American:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 10, at 7 p.m.

Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds
globenewswire.com08 August 2024 Sentiment: POSITIVE

RAMAT GAN, Israel, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,857,143 American Depositary Shares (ADSs), having an exercise price of $1.75 per ADS, issued by Can-Fite in January 2023 and November 2023. The ADSs representing ordinary shares issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form F-3 (File No. 333-276000) and Form F-1 (File No. 333-269485). The closing of the offering is expected to occur on or about August 12, 2024, subject to satisfaction of customary closing conditions.

Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer
globenewswire.com11 July 2024 Sentiment: POSITIVE

PETACH TIKVA, Israel, July 11, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it  has submitted an application to the U.S. Food and Drug Administration (FDA) for Orphan Drug Designation for its drug candidate Namodenoson in the treatment of   pancreatic carcinoma.

Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver
businesswire.com24 June 2024 Sentiment: POSITIVE

PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announces that company scientists came up with breakthrough findings showing that the anti-cancer and protective effects in the liver are conferred via the signalling protein adiponectin. This very important positive cytokine plays a pivotal role in regulating.

Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024
businesswire.com27 May 2024 Sentiment: POSITIVE

PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announces that its VP of Business Development, Dr. Sari Fishman, will hold 23 partnering meetings with Biotech & Pharma companies, who showed interest in partnering with Can-Fite. The meetings will take place during the Bio International Convention 2024 in.

Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV
Newsfile Corp01 April 2024 Sentiment: POSITIVE

Ramat Gan, Israel--(Newsfile Corp. - April 1, 2024) - Can-Fite BioPharma, Ltd. (NYSE American: CANF) announced today that it will be presenting at The 14th Annual LD Micro Invitational at the Sofitel New York on April 8th-9th, 2024.

Can-Fite (CANF) Up on Liver Cancer Study Update of Namodenoson
Zacks Investment Research22 November 2023 Sentiment: POSITIVE

Can-Fite (CANF) stock up 7% as the liver cancer patient achieves a complete response and overall survival of 6.9 years upon continued treatment with namodenoson in a phase II study.

What type of business is Can-Fite BioPharma?

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.

What sector is Can-Fite BioPharma in?

Can-Fite BioPharma is in the Healthcare sector

What industry is Can-Fite BioPharma in?

Can-Fite BioPharma is in the Biotechnology industry

What country is Can-Fite BioPharma from?

Can-Fite BioPharma is headquartered in Israel

When did Can-Fite BioPharma go public?

Can-Fite BioPharma initial public offering (IPO) was on 06 November 2012

What is Can-Fite BioPharma website?

https://www.canfite.com

Is Can-Fite BioPharma in the S&P 500?

No, Can-Fite BioPharma is not included in the S&P 500 index

Is Can-Fite BioPharma in the NASDAQ 100?

No, Can-Fite BioPharma is not included in the NASDAQ 100 index

Is Can-Fite BioPharma in the Dow Jones?

No, Can-Fite BioPharma is not included in the Dow Jones index

When was Can-Fite BioPharma the previous earnings report?

No data

When does Can-Fite BioPharma earnings report?

The next expected earnings date for Can-Fite BioPharma is 29 November 2024